Literature DB >> 12748250

Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions.

Wakako Kawabata1, Takashi Suzuki, Takuya Moriya, Keisei Fujimori, Hiroshi Naganuma, Satoshi Inoue, Yositaka Kinouchi, Kaori Kameyama, Hiroshi Takami, Tooru Shimosegawa, Hironobu Sasano.   

Abstract

Both epidemiological and experimental findings suggest the possible roles of sex steroids in the pathogenesis and/or development of various human thyroid disorders. In this study, we evaluated the expression of estrogen receptors (ER) alpha and beta in normal thyroid glands (N = 25; female: n = 13, male: n = 10, unknown: n = 2) ranging in age from fetus to adult. Furthermore, using immunohistochemistry, we investigated the expression of ERalpha and beta in 206 cases of thyroid disorders, including 24 adenomatous goiters, 23 follicular adenomas, and 159 thyroid carcinomas. In addition, we also studied the mRNA expression of ERalpha and beta and 17beta-hydroxysteroid dehydrogenase Type 1 and 2, enzymes involved in the interconversion between estrone and estradiol, using reverse transcription polymerase chain reaction (RT-PCR), in 48 of these 206 cases (10 adenomatous goiters, 10 follicular adenomas, and 28 papillary thyroid carcinomas) in which fresh frozen tissues were available for examination to further elucidate the possible involvement of intracrine estrogen metabolism and/or actions in thyroid disorders. ERalpha labeling index, or percentage of cells immunopositive for ERalpha, was significantly higher in adenomatous goiter (14.2 +/- 6.4), follicular adenoma (13.4 +/- 5.1), and thyroid carcinoma (16.4 +/- 2.1) than in normal thyroid gland (0; P <.05). Few follicular cells were positive for ERalpha in normal thyroid glands. In papillary carcinoma, ERalpha labeling index was significantly higher in premenopausal women (28.1 +/- 4.5) than in postmenopausal women (14.2 +/- 2.9) and in men of various ages (7.6 +/- 2.7; P <.05). In other histological types of thyroid carcinoma, no significant correlations were detected. ERbeta immunoreactivity was detected in both follicular and C-cells of normal thyroid glands, including those in developing fetal thyroid glands. In addition, ERbeta immunoreactivity was detected in the nuclei of various thyroid lesions. But no significant correlations were detected between ERbeta labeling index and clinicopathological findings including age, menopausal status, gender, and/or histological type of thyroid lesions. 17beta-hydroxysteroid dehydrogenase Type 1 expression was detected in 31/48 (64.0%) of the cases examined, whereas Type 2 was detected only in 3/46 (6.3%) of all the cases examined. These results demonstrated that estrogens may influence the development, physiology, and pathology of human thyroid glands, and these effects, especially through ERalpha, may become more pronounced in neoplasms, particularly in papillary carcinoma arising in premenopausal women.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12748250     DOI: 10.1097/01.MP.0000066800.44492.1B

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Are estrogen receptors alpha detectable in normal and abnormal thyroid tissue?

Authors:  Michael Vaiman; Youlian Olevson; Judith Sandbank; Liliana Habler; Sergei Zehavi; Alex Kessler
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-16       Impact factor: 2.503

Review 2.  Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage.

Authors:  Mirja Rotinen; Joaquín Villar; Ignacio Encío
Journal:  J Physiol Biochem       Date:  2012-02-29       Impact factor: 4.158

3.  Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area.

Authors:  Thérèse Truong; Laurent Orsi; Dominique Dubourdieu; Yannick Rougier; Denis Hémon; Pascal Guénel
Journal:  Am J Epidemiol       Date:  2005-06-01       Impact factor: 4.897

4.  Hormonal factors and the risk of papillary thyroid cancer in the California Teachers Study cohort.

Authors:  Pamela L Horn-Ross; Alison J Canchola; Huiyan Ma; Peggy Reynolds; Leslie Bernstein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-26       Impact factor: 4.254

5.  Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma.

Authors:  Claire Bléchet; Pierre Lecomte; Loïc De Calan; Patrice Beutter; Serge Guyétant
Journal:  Virchows Arch       Date:  2007-02-28       Impact factor: 4.064

6.  The impact of age and gender on papillary thyroid cancer survival.

Authors:  J Jonklaas; G Nogueras-Gonzalez; M Munsell; D Litofsky; K B Ain; S T Bigos; J D Brierley; D S Cooper; B R Haugen; P W Ladenson; J Magner; J Robbins; D S Ross; M C Skarulis; D L Steward; H R Maxon; S I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2012-04-10       Impact factor: 5.958

7.  FOLLICULAR THYROID CARCINOMA - CLINICAL AND DIAGNOSTIC FINDINGS IN A 20-YEAR FOLLOW UP STUDY.

Authors:  C I Badulescu; D Piciu; D Apostu; M Badan; A Piciu
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

8.  Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study.

Authors:  Nikolaos P Karidis; Constantinos Giaginis; Gerasimos Tsourouflis; Paraskevi Alexandrou; Ioanna Delladetsima; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2011-09

9.  Differential expression patterns of estrogen receptor (ER)-β splice variants between papillary thyroid cancer and nodular thyroid goiter.

Authors:  Wenwu Dong; Jing Li; Yanhong Huang; Hao Zhang; Zhongyan Shan; Weiping Teng
Journal:  Med Sci Monit       Date:  2012-09

10.  Retrospective Analysis of Patients with Synchronous Primary Breast and Thyroid Carcinoma.

Authors:  İlker Murat Arer; Hakan Yabanoğlu; Murat Kuş; Aydıncan Akdur; Tevfik Avcı
Journal:  Eur J Breast Health       Date:  2018-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.